VJHemOnc is committed to improving our service to you

EHA 2019 | Intensive chemotherapy for AML: do we still need it?

VJHemOnc is committed to improving our service to you

Christoph Röllig

Christoph Röllig, MD, Dresden University of Technology, Dresden, Germany, discusses the treatment options for acute myeloid leukemia (AML), and whether intensive chemotherapy is still clinically relevant. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter